The relationship between symptomatic and functional changes of Korean children and adolescents with attention deficit hyperactivity disorder treated with OROS methylphenidate

被引：0
|
作者：
Lee, S. [1 ]
Kim, E. [1 ]
Cheon, K. [1 ]
Song, D. [1 ]
机构：
[1] Yonsei Univ, Coll Med, Seoul, South Korea
来源：
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY | 2015年 / 24卷
关键词：
OROS-MPH; ADHD; Symptoms; Functioning; Life Participation Scale;
D O I：
暂无
中图分类号：
B844 [发展心理学（人类心理学）];
学科分类号：
040202 ;
摘要：
PS-109
引用
收藏
页码：S170 / S170
页数：1
相关论文
共 50 条
  • [21] A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder
    Stein, MA
    Sarampote, CS
    Waldman, ID
    Robb, AS
    Conlon, C
    Pearl, PL
    Black, DO
    Seymour, KE
    Newcorn, JH
    PEDIATRICS, 2003, 112 (05) : E404 - E413
  • [22] BMI Changes in Children and Adolescents with Attention Deficit Hyperactivity Disorder Before and After Treatment with Methylphenidate
    Kousha, Maryam
    Dalili, Setila
    Kiani, Seyyed Amir
    Zare, Maryam
    Karambin, Mohammad Mahdi
    Heidarzadeh, Abtin
    Koohmanaee, Shahin
    Rad, Afagh Hassanzadeh
    IRANIAN JOURNAL OF PEDIATRICS, 2018, 28 (02)
  • [23] The relationship between cognitive functional change and behavioral symptom as the result of methylphenidate in children with attention deficit hyperactivity disorder
    Park, H
    Chang, M
    Jeong, S
    Bai, D
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 : S64 - S64
  • [24] A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder
    Katzman, Martin A.
    Sternat, Tia
    CNS DRUGS, 2014, 28 (11) : 1005 - 1033
  • [25] A Review of OROS Methylphenidate (Concerta®) in the Treatment of Attention-Deficit/Hyperactivity Disorder
    Martin A. Katzman
    Tia Sternat
    CNS Drugs, 2014, 28 : 1005 - 1033
  • [26] Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder
    Rubio-Morell, B.
    Martin-Gonzalez, R.
    Herreros-Rodriguez, O.
    Gonzalez-Perez, P.
    Hernandez-Exposito, S.
    Quintero-Fuentes, I.
    Gracia-Marco, R.
    REVISTA DE NEUROLOGIA, 2008, 46 (10) : 602 - 608
  • [27] Methylphenidate in the treatment of children and adolescents with bipolar disorder and Attention-Deficit/Hyperactivity disorder
    Findling, Robert L.
    Short, Elizabeth J.
    McNamara, Nora K.
    Demeter, Christine A.
    Stansbrey, Robert J.
    Gracious, Barbara L.
    Whipkey, Resaca
    Manos, Michael J.
    Calabrese, Joseph R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2007, 46 (11): : 1445 - 1453
  • [28] Body Mass Index Changes in Children and Adolescents Treated with Methylphenidate forAttention Deficit Hyperactivity Disorder
    Kousha, Maryam
    Asli, Samaneh Hasanpour
    Eslamdoust-Siahestalkhi, Fatemeh
    Shoar, Yasmin
    Shoar, Zohreh
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2024, 18 (02) : 73 - 82
  • [29] Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder
    Wolraich, ML
    Greenhill, LL
    Pelham, W
    Swanson, J
    Wilens, T
    Palumbo, D
    Atkins, M
    McBurnett, K
    Bukstein, O
    August, G
    PEDIATRICS, 2001, 108 (04) : 883 - 892
  • [30] Academic, Behavioral, and Cognitive Effects of OROS® Methylphenidate on Older Children with Attention-Deficit/Hyperactivity Disorder
    Wigal, Sharon B.
    Wigal, Tim
    Schuck, Sabrina
    Brams, Matthew
    Williamson, David
    Armstrong, Robert B.
    Starr, H. Lynn
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2011, 21 (02) : 121 - 131
12345